Search results
Results from the WOW.Com Content Network
Non-ergoline dopamine receptor agonists have higher binding affinity to dopamine D 3-receptors than dopamine D 2-receptors. This binding affinity is related to D 2 and D 3 receptor homology, the homology between them has a high degree of sequence and is closest in their transmembrane domains, were they share around 75% of the amino acid.
Abnormal dopamine receptor signaling and dopaminergic nerve function is implicated in several neuropsychiatric disorders. [1] Dopamine receptors are therefore common drug targets. Dopamine receptors activate different effectors through not only G-protein coupling, but also signaling through different protein (dopamine receptor-interacting ...
Dopamine receptor agonists can be divided into non-selective dopamine receptor agonists, D 1-like receptor agonists, and D 2-like receptor agonists. Non-selective dopamine receptor agonists include dopamine, deoxyepinephrine (epinine), dinoxyline, and dopexamine. They are mostly peripherally selective drugs, are often also adrenergic receptor ...
The mechanisms of sympathomimetic drugs can be direct-acting (direct interaction between drug and receptor), such as α-adrenergic agonists, β-adrenergic agonists, and dopaminergic agonists; or indirect-acting (interaction not between drug and receptor), such as MAOIs, COMT inhibitors, release stimulants, and reuptake inhibitors that increase the levels of endogenous catecholamines.
These agents stimulate dopamine receptors. In doing so, they alleviate the symptoms associated with Parkinson's disease . Wikimedia Commons has media related to Dopamine agonists .
Abnormal dopamine receptor signaling and dopaminergic nerve function is implicated in several neuropsychiatric disorders. [2] Thus, dopamine receptors are common neurologic drug targets; antipsychotics are often dopamine receptor antagonists while psychostimulants are typically indirect agonists of dopamine receptors.
Several D 1 receptor agonists are used clinically. These include apomorphine, pergolide, rotigotine, and terguride. All of these drugs are preferentially D 2-like receptor agonists. Fenoldopam is a selective D 1 receptor partial agonist that does not cross the blood-brain-barrier and is used intravenously in the treatment of hypertension.
It is unclear if dopamine is safe to use during pregnancy or breastfeeding. [4] At low doses dopamine mainly triggers dopamine receptors and β1-adrenergic receptors while at high doses it works via α-adrenergic receptors. [4] Dopamine was first synthesized in a laboratory in 1910 by George Barger and James Ewens in England. [8]